Literature DB >> 9041947

Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon.

F Khan1, S J Litchfield, M McLaren, D J Veale, R C Littleford, J J Belch.   

Abstract

OBJECTIVE: To assess the effects of oral L-arginine supplementation on cutaneous vascular responses in patients with primary Raynaud's phenomenon (RP).
METHODS: Double-blind, crossover comparison of placebo versus L-arginine (8 gm/day for 28 days). Cutaneous vascular responses in the fingers were assessed during iontophoresis of acetylcholine and sodium nitroprusside, which are endothelium-dependent and endothelium-independent vasodilators.
RESULTS: In comparison with control subjects, patients with primary RP had diminished endothelium-dependent and -independent vasodilatation (P < 0.05, and P < 0.005, respectively, by analysis of variance). At the 3 doses used, vascular responses to acetylcholine were reduced by 71%, 64%, and 63%, respectively, and responses to sodium nitroprusside were reduced by 67%, 73%, and 66%, respectively. L-arginine had no significant effect on cutaneous vascular responses to acetylcholine or sodium nitroprusside in control subjects or patients with primary RP.
CONCLUSION: Reduced vasodilator ability in primary RP is unlikely to be due to an impairment in the L-arginine/nitric oxide pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041947     DOI: 10.1002/art.1780400220

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

1.  The cutaneous vasoconstrictor response to venous stasis is normal in subjects with primary Raynaud's disease.

Authors:  C M Edwards; J M Marshall; M Pugh
Journal:  Clin Auton Res       Date:  1999-10       Impact factor: 4.435

2.  Iontophoretic evaluation of vascular reactivity to acetylcholine in patients with primary Raynaud's phenomenon and systemic sclerosis.

Authors:  B Marasini; L Conciato
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

3.  Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.

Authors:  Christopher M Rembold; Carlos R Ayers
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

4.  Influence of compression pressure from the hand access device on hand microcirculation during hand-assisted laparoscopic surgery.

Authors:  S Manasnayakorn; F Khan; R A Levison; A Cuschieri; G B Hanna
Journal:  Surg Endosc       Date:  2008-10-15       Impact factor: 4.584

Review 5.  Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; S Clark
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

Review 6.  Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Authors:  F V Brozovich; C J Nicholson; C V Degen; Yuan Z Gao; M Aggarwal; K G Morgan
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

7.  Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease.

Authors:  P J Smith; C J Ferro; D S McQueen; D J Webb
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

8.  Seasonal differences in finger skin temperature and microvascular blood flow in healthy men and women are exaggerated in women with primary Raynaud's phenomenon.

Authors:  J M Gardner-Medwin; I A Macdonald; J Y Taylor; P H Riley; R J Powell
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

9.  Diagnosis of Raynaud's phenomenon by 99mTc-pertechnetate hand perfusion scintigraphy: a pilot study.

Authors:  Slavica Pavlov-Dolijanovic; Nebojsa Petrovic; Nada Vujasinovic Stupar; Nemanja Damjanov; Goran Radunovic; Dragan Babic; Dragana Sobic-Saranovic; Vera Artiko
Journal:  Rheumatol Int       Date:  2016-10-25       Impact factor: 2.631

10.  Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide.

Authors:  J P Noon; B R Walker; M F Hand; D J Webb
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.